Objective of the analysis 3 Our insight into the dyslipidemia market 4
CHAPTER 2 - MARKET DEFINITION AND OVERVIEW 10.
Market definition for this report 10 Current market situation 11 The statins market 12 Fibrates 13 Other classes of anti-dyslipidemics 15 Strategic scoping and focus 16
CHAPTER 3 - COUNTRY MARKET ASSESSMENTS 18.
Current and future opportunities and threats in the anti-dyslipidemic market 18 Global opportunities and threats 18 Opportunities 18 Threats 22 US: opportunities and threats 24 Opportunities 24 Threats 24 Japan: opportunities and threats 28 Threats 29 Europe: opportunities and threats 31 Opportunities 31 Threats 32 Summary of environmental issues affecting the antidyslipidemic market size 36
CHAPTER 4 - FORECAST ANALYSIS 37.
Assumptions and events 37 Trial results 37 New product launches 38 Patent expiries 40 Statins patent expiries 41 Limitations of data 42 Forecasts 42
CHAPTER 5 - COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 43.
Introduction 43 Case study 1 43 Commercial impact of Zetia and Vytorin 43 Challenges in the dyslipidemia market 43 Case study 2 48 Managing the lifecycle of Lipitor 48 Lipitor has become the gold-standard statin 48 Innovation and genericization threaten Lipitor monotherapy 48 Combination therapy as a way to extend Lipitor’s life 49 APPENDIX A – MAJOR BRAND KEY FACTS 52 Statins market data 52 Lipitor 52 Zocor 53 Pravachol 54 Crestor 55 Vytorin 56 Fibrates market data 57 Lipanthyl/Tricor 57 Cedur/Bezatol 58 Other antidyslipidemics market data 59 Zetia 59 Niaspan 60 Epadel 61 WelChol 62 Questran 63 APPENDIX B 64 Bibliography 64 Epidemiology 64 US 64 Japan 64 France 64 Germany 64 Italy 65 Spain 65 UK 65 Clinical trial data 65 Report methodology 73 Standard units 73 Japanese market data 74 About Datamonitor 75 About Datamonitor Healthcare 75 About the Cardiovascular Disease analysis team 76 Disclaimer 77
